Brandon Beylo: Vertex Pharma acquires Crinetics Pharma at 100 percent premium

Brandon Beylo: Vertex Pharma acquires Crinetics Pharma at 100 percent premium
Vertex acquires Crinetics at premium

Brandon Beylo reports that Vertex Pharma has acquired Crinetics Pharma for a 100 percent premium to today's closing price.

He observes that merger and acquisition activity in the biotech sector is accelerating.

Beylo has previously commented on market inflection points in other asset classes. In March, he suggested that gold could be nearing a bottom but might still drop to $3,800 per ounce before recovering. He later questioned whether gold trading at $4,000 would be viewed as a rare opportunity in the future. These observations highlight his continued focus on significant market moves.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.